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ABSTRAK 
 
Pendahuluan: Rawatan trombolisis merupakan salah satu kaedah bagi merawat  ST 
elevasi infarksi miokardium (STEMI) meskipun intervensi koronari perkutaneus (PCI) 
diketahui merupakan rawatan piawaian yang mantap. Kajian perfusi myokardium 
(MPS) merupakan salah satu modaliti diagnostik yang boleh digunakan bagi stratifikasi 
risiko selepas STEMI. Oleh itu, kajian ini secara khusus dijalankan untuk melihat 
pesakit dengan sejarah thrombolysis selepas STEMI dan hasil pengurusan mereka, 12 
bulan selepas MPS asas. 
Objektif: Untuk mengkaji peranan MPS dalam meramalkan hasil pengurusan pesakit 
dengan STEMI yang baru didiagnosis.  
Kaedah: Pesakit yang telah didiagnosis STEMI dengan rawatan thrombolisis  yang 
dirujuk untuk MPS disertakan dalam kajian ini. Keputusan MPS termasuk analisa 
separa kuantitatif keterukan ischaemia,  jumlah perbezaan skor (SDS), pecahan ejeksi 
ventrikel kiri (LVEF), volum akhir diastolik (EDV), dan volum sistolik akhir  (ESV) 
diperolehi. Susulan dilakukan 12 bulan selepas MPS asas dijalankan. Hasil primer 
pada pengurusan dengan hasil sekunder dikaji berkaitan dengan penemuan MPS.  
Keputusan: Tujuh orang pesakit mengalami serangan jantung kritikal (cardiac hard 
events) 12 bulan selepas MPS asas. Kesemuanya adalah lelaki dengan purata umur 
54.3 tahun. Analisa keputusan MPS dan hasil primer mendapati iskemia sederhana 
dan teruk, SDS bernilai 5 - 6 (OR = 49.875; 95% CI 11.30 – 220.16), SDS bernilai  ≥7 
(OR = 39.35; 95% CI 10.51 – 147.35), dan LVEF ≥35% mempunyai peluang 
peningkatan tidak disesuaikan yang signifikan untuk revaskularisasi. Iskemia 
sederhana dan teruk (OR = 285.8; 95% CI 28.15 - 2902.08) dan LVEF ≥ 35% (OR = 
54.04; 95% CI 6.10 – 478.56) mempunyai peluang peningkatan yang signifikan untuk 
revaskularisasi apabila diselaraskan kepada factor-faktor lain yang mengelirukan 
	 X	
dalam analisis multivariasi. Sementara itu, LVEF of 23.7% dengan julat 17-29% (OR = 
0.593; 95% CI 0.39 – 0.9), EDV of 172.6 ml dengan julat 155-197 mls 	
 (OR = 1.13; 95% CI 1.05 – 1.21), dan ESV of 130.9 ml dengan julat 110-141 mls 	
 (OR = 1.16; 95% CI 1.03 –1.31) mempunyai peluang peningkatan  tidak disesuaikan 
yang ketara dalam kejadian serangan jantung kritikal. 	
Kesimpulan:   MPS mempunyai peranan dalam meramalkan hasil pengurusan pesakit 
yang baru didiagnosis STEMI 12 bulan selepas MPS asas. 
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ABSTRACT 
 
Background: Thrombolytic therapy is one of the treatment modality in ST elevation 
myocardial infarction (STEMI) although percutaneous coronary intervention (PCI) is an 
established gold standard treatment. Myocardial Perfusion Study (MPS) is one of the 
diagnostic modalities that can be used for risk stratification post STEMI. The purpose 
of this research is to study the role of MPS in predicting the management outcome in 
newly diagnosed STEMI patients.  
Methods: Post STEMI with thrombolytic treatment referred for MPS were included in 
this study. MPS findings including semi quantitative analysis of severity of ischaemia, 
automated summed difference score (SDS), left ventricular ejection fraction (LVEF), 
end diastolic volume (EDV) and end systolic volume (ESV) were obtained. Follow up 
was done 12 months after baseline MPS. Primary outcome on types of management 
with secondary outcome were studied in relation to MPS findings.  
Results: Seven patients had encountered cardiac hard events 12 months after the 
baseline MPS. All were male with mean age of 54.3 years old. Analysis of MPS 
findings and primary outcome found that moderate to severe ischemia, SDS of 5 - 6 
(OR = 49.875; 95% CI 11.30 – 220.16), SDS of ≥7 (OR = 39.35; 95% CI 10.51 – 
147.35), and LVEF ≥35% had significant unadjusted increased chance for 
revascularisation. Moderate to severe ischemia (OR = 285.8; 95% CI 28.15 - 2902.08) 
and LVEF ≥ 35%(OR = 54.04; 95% CI 6.10 – 478.56) had significant increased chance 
for revascularisation when adjusted to other confounding factors in multivariate 
analysis. Meanwhile LVEF of 23.7% with range 17-29% (OR = 0.593; 95% CI 0.39 – 
0.9), EDV of 172.6 ml with range 155-197 mls (OR = 1.13; 95% CI 1.05 – 1.21), and 
ESV of 130.9 ml with range 110-141 mls (OR = 1.16; 95% CI 1.03 –1.31) had 
significant unadjusted increased chance of cardiac hard events.  
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Conclusion: MPS has a role in predicting the management outcome of patients with 
newly diagnosed STEMI post thrombolysis, 12 months after baseline MPS.  
Keywords:  Tc-99m Tetrofosmin Myocardial Perfusion Imaging, Myocardial 
infarction, cardiac death, heart failure. 
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1.0 INTRODUCTION 
Myocardial infarction (MI) is defined as myocardial cell death due to prolonged 
ischaemia.  It is one of the five main manifestations of coronary artery disease. Acute 
MI is classified into two groups, which are ST elevation MI (STEMI), and Non STEMI. 
Other manifestations include stable angina, unstable angina, heart failure and sudden 
death. Raising numbers of acute ST elevation myocardial infarction (STEMI) in 
Malaysia is associated with morbidity and mortality where is has contributed 20-25% of 
all deaths in public hospitals (Zambahari and Selvadurai, 2014).  
Current treatment of STEMI is depending on the availability of percutaneous 
coronary intervention (PCI) at the hospital. In a PCI center hospital, the 
recommendation is to do primary PCI within 120 minutes following an acute MI. 
Thrombolytic treatment is given to patients in non PCI center or patients presented 
more than 120 minutes from time of diagnosis(Zambahari and Selvadurai, 2014). 
Thrombolytic treatment works by lysing infarct artery thrombi and achieving reperfusion 
thus restricting the infarct size, preserving the ejection fraction, and improving survival 
(White and Van de Werf, 1998). Within ninety minutes of presentation, thrombolytic 
treatment is at its most efficient to achieve infarct artery patency in around 50% of 
patients (White and Van de Werf, 1998).  
Primary PCI is recommended over thrombolytic therapy but if PCI cannot be 
performed, thrombolytic therapy can be given within 12 hours of onset of symptoms 
with persistent ST segment elevation on the electrocardiogram (ECG) (White and Van 
de Werf, 1998). Thrombolytic treatment have improved survival at long term follow up 
yet the therapy is not always followed by reperfusion of the artery or thrombus 
dissolution which may cause the incidence of post infarction angina or recurrent 
ischemia. Delayed selective angiography plays a role after thrombolysis on 
haemodynamically unstable patients or residual ischaemia (Zambahari and Selvadurai, 
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2014).  
Early and late risk stratification is divided into clinical and non invasive imaging.  
Clinical risk stratification using thrombolysis in myocardial infarction (TIMI) score or 
Global Registry of Acute Coronary Events (GRACE) calculator is done to estimate the 
prognosis of the patient and to weigh whether patient might benefit from intervention 
(Zambahari and Selvadurai, 2014). Therefore, it is essential to re-stratify patients post 
STEMI after thrombolytic treatment. Risk stratification post MI is assessed using Multi-
sliced Computed Tomography (MSCT), Cardiac Magnetic Resonance Imaging (CMR), 
Myocardial Perfusion SPECT (MPS) or Positron Emission Tomography (PET-
CT)(Zambahari and Selvadurai, 2014). It is done to prognosticate the risk of cardiac 
death by assessing the left ventricular ejection fraction (LVEF) and detection of 
residual myocardial ischemia (Zambahari and Selvadurai, 2014). 
 Technetium-99m Tetrofosmin MPS with stress and rest study is currently a 
valuable prognostic test in coronary artery disease (CAD)(Hendel et al., 2009). Studies 
have shown that MPS is able to prognosticate future cardiac events (Nishimura et al., 
2008). Generally, it also served as a diagnostic tool to determine the necessity for 
catheterisation (Hachamovitch et al., 2006).  Therefore MPS has been a routine 
modality for patients with diagnosed CAD. However, in this PCI era, not much literature 
was done to look at the patients’ post thrombolytic treatment who did not underwent 
PCI during the acute phase.  This study is specifically carried out to look at the patients 
with history of STEMI post thrombolysis and their management outcome 12 months 
after baseline MPS. 
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2.0 LITERATURE REVIEW 
2.1 Overview of Myocardial Infarction 
Myocardial infarction (MI) is caused by a sudden ischaemic death to the 
myocardial tissue. It is commonly due to thrombotic occlusion of a coronary vessel 
caused by rupture of a vulnerable plague (Frangogiannis, 2015). Meanwhile, 
myocardial ischaemia occurred due to imbalance between oxygen supply and demand. 
In severe atherosclerosis with >75% luminal narrowing, it does not cause any reduction 
of blood flow during rest.  Type 1 MI or spontaneous MI resulting from coronary 
atherosclerotic disease complicated by superimposed thrombosis plague is the most 
common cause of thrombosis as a gap in fibrous cap of a vulnerable plague exposes 
the necrotic core to the blood stream and has potent thrombogenic response 
(Frangogiannis, 2015). 
There are a few other clinical classifications of MI including Type 2 MI which is 
secondary to an ischemic imbalance. It is a condition where myocardial injury with 
necrosis causing imbalanced between myocardial oxygen supply and demand is 
contributed by other than factors of CAD such as coronary endothelial dysfunction, 
coronary artery spasm, coronary embolism, arrhythmias, anemia, respiratory failure, 
hypotension, and HPT with or without LV hypertrophy(Zambahari and Selvadurai, 
2014, White et al., 2014). 
Acute coronary syndrome is a clinical spectrum ranging from unstable angina 
(UA) or Non STEMI (NSTEMI) to STEMI. Clinical presentation is usually based on the 
severity of coronary occlusion. It is a clinical diagnosis based on the presence of 
myocardial injury or necrosis as indicated by a rise and fall of serum cardiac 
biomarkers. It should beforehand present with clinical history consistent with chest pain 
of ischaemic origin, ECG changes of ST segment elevation or presumed left bundle 
	 4	
branch block (LBBB). In unstable angina, cardiac biomarkers are normal but increased 
in NSTEMI. The distinct clinical feature separating unstable angina or NSTEMI with 
STEMI is the presence of ST segment elevation in ECG. Both spectrum of disease has 
different ways of management. While thrombolytic treatment is essential for patients 
with STEMI, it is contraindicated for patients with unstable angina or NSTEMI. (Wessler 
et al., 2015).  
Chest pain of STEMI starts at sudden onset and should lasts >30minutes. It is 
centrally located and may radiate to the jaw and down to the left arm. The 
characteristics of pain is usually described as a pressure, squeezing or severe 
crushing pain with associated sweating, nausea and shortness of breath. In the elderly, 
females and diabetic patients may present with atypical symptoms where clinician 
should put their high suspicion towards these high risk group (Zambahari and 
Selvadurai, 2014). 
Troponins have near absolute specificity and high sensitivity for myocardial 
infarction where it rises 3-4hours of onset of MI and more likely to be positive after six 
hours. However to date, troponins namely cardiac troponin T(cTnT), cardiac troponin I 
(cTnI) were the best cardiac biomarkers for diagnosing MI and usually combined with 
creatine kinase-MB (CKMB) and myoglobin (Ahmad and Sharma, 2012). A more 
comprehensive definition of MI which utilises newer cardiac biomarkers such as heart 
type fatty acid binding protein, high sensitivity cardiac Troponin (hs-Tn) and copeptin 
together with imaging technique is more sensitive in diagnosing MI (Zambahari and 
Selvadurai, 2014).  
Patients with acute coronary syndrome present at a mean age of 59±12years, 6 
years younger than those in Global Registry of Acute Coronary Events (GRACE) 
(Zambahari and Selvadurai, 2014). Age is one of the significant predictor to outcome of 
survival at 1-year post MI. According a study, the mean age of 61(51,59) survived 
whilst mean age of 70(62,79) died after 1 year of diagnosis (Califf et al., 2000). CAD 
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generally affects men more than women although women had higher 6 month mortality 
if affected (Seong and John, 2016). From National Cardiovascular Disease-Acute 
Coronary Syndrome (NCVD-ACS) registry, 75.8% out of patients diagnosed ACS were 
male while another 24.2% were female(Lu et al., 2014). 
Based on race, Indians were over represented in comparison to the general 
proportion of the ethnicities. (Seong and John, 2016). The prevalence of diabetes 
mellitus among Asians is more common compared to Caucasians in the two studies 
done in Birmingham and Kuala Lumpur (Seong and John, 2016). Seong et al. 2016 
also reviewed that Chinese had higher prevalence of hypertension and dyslipidaemia 
whilst the Indians had higher rates of diabetes mellitus. (Seong and John, 2016).  
A study measuring BMI in patients post MI revealed that increasing BMI has 
increased risk of recurrent coronary events. Mild overweight (BMI 25 to 27.4) has 
relative risk of 0.93 and it has increased to 1.8 for class II-III obesity (BMI>35)(Rea et 
al., 2001). 
 
2.2 Management of Myocardial Infarction 
In acute setting, primary PCI remains the gold standard of treatment in treating 
STEMI. However, the efficacy of PCI has always been limited when there is delayed in 
restoration of the infarcted coronary artery. The ideal time for reperfusion strategy 
either by primary PCI or thrombolytic treatment, from the onset of angina is 180 
minutes (Zambahari and Selvadurai, 2014). Although primary PCI is more effective 
than thrombolysis, the advantage of primary PCI is exceptionally prone to treatment 
delays (Gershlick et al., 2013). A multivariate analysis which adjusted for other 
predictors of mortality recommend that system delay is independantly associated with 
mortality (Terkelsen et al., 2010). Another study on the other hand concluded that 
primary PCI is associated with significantly reduced 30 day mortality compared with 
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fibrinolysis irrespective of treatment delay and therefore despite logistic issues, the 
standard approach should be PCI for all patients with STEMI (Boersma, 2006). 
Meanwhile, other studies showed that patient who came earlier within 2 hours of 
angina symptoms and received early thrombolysis had no significant reduction in 1 
year mortality rates compared with patients who came in early and treated with PCI 
(Lambert et al., 2010, Armstrong, 2006, Westerhout et al., 2011). Another study 
recommended that thrombolysis should be carried out early preferably at pre hospital 
level to patients with no contraindications and followed by coronary angiography (within 
24 hours) or rescue PCI for those thrombolytic failure (Bonnefoy et al., 2002).  A study 
showed that more than 70% of patients receiving early thrombolysis had TIMI flow 
grades of 2-3 compared with 20% of those arriving for primary PCI which means 
thrombolysis has a role to reduce the infarct size in STEMI (Armstrong et al., 2013). 
According to Malaysian guidelines, the suitable and timely use of some form of 
reperfusion treatment is more vital than the selection of therapy. Patients presented 3 
hours of onset of angina are at low risk where both treatment strategies appear to have 
similar benefit (Zambahari and Selvadurai, 2014). In majority of hospital in Malaysia, 
thrombolysis is more readily available and plays as the main reperfusion strategy in 
patients with STEMI (Zambahari and Selvadurai, 2014). There are two options for 
thrombolytic treatment which are intravenous (i.v) Streptokinse or 
Tenectaplase/Metalyse. Being the most popular, Streptokinase which is not a fibrin 
specific agent results in a lower patency rate of occluded vessel at 60 minutes 
compared to fibrin specific agents (Zambahari and Selvadurai, 2014). 
Tenectaplase/Metalyse on the other hand results to a more rapid restoration of the 
infarcted artery than streptokinase. Heparin or enoxaparin should also be given 
following completion of thrombolysis therapy (Zambahari and Selvadurai, 2014).  
While optimum management of STEMI with primary PCI is still controversial, 
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very limited study had shown the role of MPS for decision making of revascularisation 
(Meliga et al., 2011). A study of patients using Tc-99m Sestamibi MPS was done 
looking at the viability of the myocardium post thrombolysis where the study found that 
redistribution of regional wall and improvement of wall motion indicate viable 
myocardium (Javadi et al., 2011).  
Antiplatelet agents such as Aspirin is indicated in all patients at diagnosis and 
should be continued unless contraindicated. Clopidogrel with aspirin have shown to 
reduced risk of death, reinfarction without increasing the risk of bleeding  or 
cerebrovascular disease (group, 2005). Other drugs of choice include β blockers, 
Angiotensin converting enzyme inhibitor (ACE-I) and Angiotensin Receptor Blocker 
(ARB) (if ACE-I intolerant). β blockers which was already established as a beneficial 
long term treatment in the prethrombolytic era is indicated in patients with heart failure 
or LV dysfunction. ACE-I should be considered in the treatment and when there is 
intolerance it can be replaced with ARB (Zambahari and Selvadurai, 2014, O'Gara et 
al., 2013).  Lipid lowering therapy is also initiated regardless of initial cholesterol levels 
and is to continue indefinitely (Pedersen et al., 2005). A study showed that with optimal 
medical therapy in patients who survived the acute phase of STEMI regardless 
whether PCI was commenced, reduced the mortality rates in 2 years follow up (García-
García et al., 2017). 
 
2.3 Prognostication of Myocardial Infarction 
 
Patients with history of STEMI are at increased risk of subsequent morbidity 
and mortality due to complications such as heart failure and late onset arrhythmias. 
Therefore continuous risk stratification using dynamic TIMI risk score in patients with 
STEMI is essential. It is a significant clinical tool to estimate 1 year mortality. A review 
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on dynamic TIMI risk scoring estimated 1 – 5% mortality in one year among low to 
moderate risk patients with TIMI score of ≤5; and 8 – 25% mortality among patients 
with TIMI risk score of >5 (Amin et al., 2013). Risk stratification of patients post STEMI 
is necessary for prognostication and to identify further management. Patients who were 
not managed with coronary angiography should be risk stratified early. Myocardial 
perfusion study is one of the modalities to look at the left ventricular function and the 
presence of myocardial ischemia (Zambahari and Selvadurai, 2014, O'Gara et al., 
2013).   
Nishimura T (2008) has classified the cardiac outcome in his study into 
presence of cardiac hard events or no hard events. The cardiac hard events include 
death, severe heart failure or myocardial infarction. The result showed 2.4% 
encountered cardiac hard events during 3 year follow up. Hachamovitch et al (2003) 
also defined the outcome as presence of cardiac events i.e death, myocardial 
infarction, severe heart failure whilst no hard events is defined as asymptomatic of 
cardiac disease. CAD was the main cause of heart failure (49.5%) followed by 
hypertension (18.6%). (Seong and John, 2016). 
2.4 Role of Nuclear Cardiology 
Myocardial perfusion study (MPS) is one of the non-invasive images of the 
myocardium. Two most common used isotopes are Thallium-201 and Technetium-99m 
and imaging acquisition used is SPECT. MPS using SPECT have been largely 
replacing the previous multiple views planar images due to its superiority in the 
standpoint of localisation, quantification and image quality. MPS is done at rest and 
during stress to produced images of myocardial regional uptake that reflect relative 
regional myocardial blood flow (Gibbons, 2000). During stress vasodilator, myocardial 
blood flow is typically increased three to five fold compared to rest. With significant to 
coronary stenosis myocardial perfusion will not increase appropriately in the territory 
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supplied by the artery with the stenosis (Ziessman et al., 2013).  
Many types of coronary vasodilators can be used for stress the heart 
pharmacologically. Dypiridamole for instance, is practically used in this study acts by 
blocking the cellular re-uptake of adenosine thus resulting in coronary vasodilatation 
and subsequent increased in coronary blood flow. Therefore in a significant coronary 
stenosis, the vasodilator would reduce perfusion at the sclerotic area (steal 
phenomenon) without inducing true ischemia(Ziessman et al., 2013, De Carvalho et al., 
2017).   Contraindications include second or third degree heart block, bronchospasm 
such as bronchial asthma and chronic obstructive airways disease. Dobutamine on the 
other hand is used when patients are contraindicated to Dypiridamole. It is a 
sympathomimetic drugs that mainly acts on β1 cardiac receptors causing positive 
inotropic and chronotropic effects. Apart from its short half life (2min), and slight 
vasodilatory effect due to less β2 receptor mechanism, patients on β-blockers need to 
witheld their medication 24-48hours since it will interfere with Dobutamine efficacy(De 
Carvalho et al., 2017, Ziessman et al., 2013).  
Tc-99m-1,2-bis[bis(2-ethoxyethyl) phosphino] ethane (tetrofosmin) has been 
used for SPECT study in which the pharmacokinetics is similar to Tc-99m-2-
methoxyisobutylisonitrile (sestamibi). It is a cationic complex that diffuses passively 
through the capillary and cell membrane. It then trapped in the mitochodria and 
retention is based on the intact mitochondria reflecting viable myocytes. Tetrofosmin is 
cleared rapidly from blood and approximately 1.2% of the administered radiotracer is 
taken up by the myocardial cells (Hesse et al., 2005, Ziessman et al., 2013). It is also 
known that the Tc-99m agents have better characteristics compared to Thallium (Tl-
201) which is already out of market. Tc-99m agents have higher energy (140kEV) and 
hence resulting better image quality due to less attenuation and scatter. Having short 
half life approximately 6 hours, it also has low radiation exposure towards patient 
(Ziessman et al., 2013, Hesse et al., 2005). 
	 10	
Semi quantitative analysis of SPECT used short axis, horizontal long axis and 
vertical long axis tomography divided into 17 segments. Each segment was scored by 
consensus of two expert observers using five-point scoring system namely 0=normal; 
1=equivocal; 2=moderate; 3=severe; 4=absence of tracer uptake (Cerqueira et al., 
2002). It is reported to be a known comparable prognostic value to that of automatic 
quantitative analysis (Berman et al., 1998). Another automated semiquantitative 
analysis, summed difference score (SDS) reflected the burden of ischaemia in MPS.  It 
is derived from the difference between summed stress score (SSS) and summed rest 
score (SRS). An SDS of   ≥7 defined large amount of ischaemia and patient should 
undergo revascularisation (Hachamovitch et al., 2003). 
Although cardiac stress MRI is the preferred and best method due to its detailed 
anatomical description, MPS is comparable to the standard in evaluating the 
myocardial perfusion (De Carvalho et al., 2017).  A study has found that MPS has 
equivalent value compared to cardiac MRI in terms of sensitivity and specificity for 
detection of angiographically significant stenosis (Cremer et al., 2014). Other nuclear 
imaging such as cardiac perfusion Positron Emission Tomography/Computed 
Tomography (PET/CT) and Multi-sliced Computed Tomography (MSCT) is another 
known modality for perfusion evaluation (Ziessman et al., 2013, Okada et al., 2010). 
Other modalities such as stress echocardiography has similar negative predictive value 
as SPECT MPS which is around 94-99%(Metz et al., 2007). 
A study by Sharir et al (2001) found that with large amount of ischemia with 
severe left ventricular dysfunction; left ventricular ejection fraction (LVEF) of less than 
30% would increased cardiac death rate to >4% per year. The author also provided a 
risk stratification by post stress LVEF and amount of inducible ischemia (Sharir et al., 
2001).  Meanwhile another study has concluded that LVEF more than 50% predicted 
low event rate of less than 5% in 1 year and the rate increased to 27% in those with 
LVEF of less than 20%(Mahmarian et al., 2006). 
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Patients with severe coronary artery disease, angina, viable myocardium and 
reversible ischaemia with mild LV dysfunction (LVEF more than 35%) are more likely to 
benefit from revascularisation (Zambahari and Selvadurai, 2014). Medical therapy 
showed a survival advantage over patients undergoing revascularisation in the setting 
of no or mild ischaemia, whereas patients undergoing revascularisation had an 
increasing survival benefit over patients undergoing medical therapy when moderate to 
severe ischaemia was detected. Patients with more than 20% ischaemic myocardium 
showed that revascularisation had a lower cardiac mortality compared with medical 
therapy (Hachamovitch et al., 2003). Hachamovitch et al (2003) also stated that 
revascularisation does not improve survival over medical therapy in patients without 
ischemia or viable myocardium. A study by Mahmarian et al. (2006) concluded that 
patient with small perfusion defect less than 10% and LVEF more than 35% were 
discouraged from undergoing coronary angiography unless symptomatic or 
hemodynamically unstable. Infarct free survival at 1 year was calculated to be >95% in 
low risk patient(Mahmarian et al., 2006). Another study also found that 
revascularisation is associated with lower incidence of MI by 5.6% compared to 
conventional treatment (Madsen et al., 1997).  
 
2.5 Myocardial Perfusion SPECT in Malaysia 
 Currently in Hospital Sultanah Aminah Johor Bahru (HSAJB), patients with 
STEMI are managed using the guidelines from Management of STEMI 2014 produced 
by Academy of Medicine of Malaysia which mainly focused on spontaneous MI (MI 
type 1) with ST segment elevation on ECG. Patients with high risk TIMI score (score 6 
or more) are appointed for in patient or early coronary angiography. Primary PCI is 
established as a potent reperfusion strategy compared to thrombolytic treatment in 
patients with STEMI with its ability to reduced short term death from 9% to 7% (Keeley 
et al., 2003). However, this practice is still limited by facilities and expertise at our 
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center. The NCVD-ACS report 2011 by Lu et al (2014) found that utilisation rates for 
elective and emergency PCI and CABG was low and the predominant treatment of 
choice for STEMI was thrombolytic treatment which accounted for >70% of patients.  
Most of the time those with low and moderate risk TIMI score (score 5 or less) 
were referred for other imaging modalities as outpatients for risk re-stratification in 
which MPS was one of the most feasible procedure to be done. MPS has been a 
routine method and has become the gatekeeper prior to any cardiac intervention. 
Therefore this study was done to assess the usefulness of MPS particularly in patients 
post STEMI. 
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3.0 OBJECTIVES 
3.1 GENERAL OBJECTIVES 
1. To study the role of MPS in predicting the management outcome in patients 
with newly diagnosed STEMI, 12 months after baseline MPS. 
3.2 SPECIFIC OBJECTIVES 
1. To determine the association between severity of myocardial ischemia, 
LVEF, EDV, ESV and SDS noted on MPS and the management of patients, 
12 months after baseline MPS 
2. To determine the proportion of cardiac hard events among patients, 12 
months after baseline MPS 
3. To determine the correlation between the management of patients, 12 
months after baseline MPS and the presence of cardiac hard events. 
3.3 RESEARCH HYPOTHESIS 
3.3.1 Null hypothesis 
Tc-99m Tetrofosmin myocardial perfusion study (MPS) has no role 
in predicting the management outcome in patients with newly 
diagnosed STEMI, 12 months after baseline MPS. 
 
3.3.2 Alternate hypothesis 
Tc-99m Tetrofosmin myocardial perfusion scan (MPS) has a role 
in predicting the management outcome in patients with newly 
diagnosed STEMI, 12 months after baseline MPS. 
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3.4 RATIONALE OF THE STUDY 
 
This study is to determine whether MPS is a useful modality for the 
referring team in decision making for revascularisation in patients with 
history of STEMI. 
 
3.5 BENEFIT OF THE STUDY 
 
This study is to establish risk stratification for patients with history of 
STEMI. 
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4.0 METHODOLOGY 
4.1 RESEARCH DESIGN 
A retrospective and prospective cohort study was carried out in Department of 
Nuclear Medicine, Hospital Sultanah Aminah Johor Bahru (HSAJB) from March 2015 
till December 2016. 
 
4.2 PATIENT SELECTION  
Patients with history of STEMI referred for MPS in HSAJB, who fulfilled the 
inclusion and exclusion criteria and consented to participate in this study were 
included. 33 patients were retrospectively recruited and 70 patients were prospectively 
enrolled in this study. 
 
4.3 SAMPLE SIZE CALCULATION 
 
Sample size calculation was done based on study by Nishimura T (Prognostic 
study of risk stratification among Japanese patients with ischaemic heart disease using 
gated MPS: J-Access study). This study needed 91 patients to achieve 5.0% precision 
in estimating prevalence which may be about 6.7% (3) with CI=95%. Sample size 
calculation Software : SSCPS version 1.0.03-3.xls 
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4.4 INCLUSION AND EXCLUSION CRITERIA 
4.4.1 Inclusion Criteria 
o First episode of STEMI, evidenced by typical/atypical chest pain, 
ECG changes (ST segment elevation or new onset LBBB) and 
increased in cardiac enzymes level. 
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o Post intravenous thrombolysis with either intravenous (i.v) 
Streptokinase or i.v Metalyse. 
o Referred to Nuclear Medicine Department HSAJB for MPS. 
4.4.2 Exclusion Criteria 
o Patients who had undergone Coronary Artery Bypass Surgery 
(CABG) or Percutaneous Coronary Intervention (PCI). 
o Patients with congestive heart failure, vulvular heart disease or 
congenital heart disease. 
o Patients with other complications such as chronic kidney failure, 
cerebrovascular disease. 
o Normal or infarction with no ischaemia in MPS findings. 
4.5 STUDY PROTOCOL 
 
Patients with history of STEMI post thrombolysis and referred for MPS were 
identified. Explanation regarding the protocol of MPS was carried out after inclusion 
and exclusion criterias were determined.   
Patients background and clinical history were obtained. Demographic datas 
such as age, gender and race were confirmed from patients’ identification cards. 
Patients’ weight in kilogram(kg) and height in meter(m) were then measured. Detail 
background medical illnesses including history of STEMI, diabetes mellitus (DM), 
hypertension (HPT), dyslipidaemia, bronchial asthma or chronic obstructive airways 
disease were obtained. Smoking history and family history of IHD were also obtained. 
Variables definitions 
• Age/Gender/Race – confirmation from identification cards 
• BMI – Formula of Weight(kg) divided by Height(m) x Height(m) 
• Diabetes Mellitus – Confirmation by medical records or diabetic drugs or 
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prescriptions brought by patients. 
• Hypertension – Confirmation by medical records or antihypertensive 
drugs or prescriptions brought by patients. 
• Dyslipidemia - total cholesterol level more than 5.2mmol/l,  High density 
lipoprotein cholesterol (HDL-C) less than 1.0 mmol/L (males) less than 
1.2 mmol/L (females) and/or  Triglycerides (TG) more than 1.7 mmol/L 
(Zambahari and Rajadurai, 2017). 
• Smoking history - Active smoker defined as smoking >100 cigarettes 
(including hand rolled cigarettes or cigars) in their lifetime and has 
smoked in the last 28 days. Non smoker or no history of smoking is 
someone who has not smoked greater than 100 cigarettes in their 
lifetime and currently not smoking (Zealand, 2015) 
• Family history of IHD - obtained from patients’ history of family either 
parents, offspring or siblings who suffered from premature CAD (men 
less than 55years old and women less than 65years old). 
 
4.5.1 Stress study  
 
All patients were given counselling and provided with a brochure containing 
instructions and preparation checklist before the MPS. Fasting for at least 4 hours prior 
to the study was mandatory. Patients need to withold caffeine intake, medications such 
as Aminophylline, Nitrates and β blockers (Ziessman et al., 2013). Pharmacological 
stress test with iv Dypiridamole 142mcg/kg/min was used. However, when 
contraindicated in patients with history of bronchial asthma or chronic obstructive 
airways disease, iv Dobutamine 10mcg/kg/min and was titrated till 40mcg/kg/min was 
used instead. Patients were attached to  vital signs (blood pressure and 
electrocardiogram) monitoring before the study started. Slow bolus injection of 
	 19	
Dypiridamole will take place for about 4 minutes. Subsequently, injection of 
radiopharmaceutical (Tc-99m Tetrofosmin 250MBq-400MBq) was given at 8th minute 
from the time the procedure started.  Instead, when the  iv Dobutamine was used, it 
was infused until the targeted heart rate of the patients were achieved, before the 
radiopharmaceutical being injected.  Targeted heart rate should be achieved at 80 % of 
maximum targeted heart rate. The maximum heart rate was calculated with formula of 
220 minus by age. The adverse effects of the drugs were observed, and presence of 
chest pain and shortness of breath was observed and recorded.  
Patients were acknowledged regarding the risk of ACS characterised by chest 
pain with or without ECG changes (ST segment elevation or new onset LBBB) during 
stress study which is 2 in 10000. The ST segment depression is also recorded if at all 
present in this study.  If patients were to have the adverse effects, after iv 
Dypiridamole, a reversal drug (iv Aminophylline 250mg stat) was given. Meanwhile, if 
the patients injected with iv Dobutamine encountered adverse effects, the procedure 
would be abandoned and subjects were treated accordingly. The overall time taken for 
the study is about 15 minutes with vital signs monitoring every 3 minutes. Stress 
imaging was performed 60 minutes after the pharmacological stress study was done.  
 
4.5.2 Rest study 
 
Meanwhile rest study was done on the same day following the stress study. 
Patients were given sublingual glyceryl trinitrate (GTN) 10-15min before injection of 
400MBq-500MBq Tc-99m Tetrofosmin three hours after the stress study. GTN was 
given to reduce resting hypoperfusion and especially in patients with severe defect 
during stress study (Hesse et al., 2005, Strauss et al., 1998).  Rest imaging was done 
on dual head gamma SPECT camera with three chest lead electrodes used for ECG 
gating 60 minutes after the injection of radiopharmaceutical 
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4.5.3 Imaging Acquisition 
 
Imaging was performed with dual head gamma camera (Siemens Symbia E) 
which was equipped with low energy, high resolution collimator (LEHR) and an energy 
interval of 140±7.5%keV in a 128x128 matrix resolution. Myocardial images were 
acquired in a 180° orbit with 25 seconds readings every 3° producing raw data 
projections. Transverse reconstruction is automatically applied in the quantitative 
Gated SPECT (QGS) process using ramp filter, and 180 filtered back projections. The 
SPECT images recorded post acquisition were reviewed by the primary investigator or 
medical officers in the Nuclear Medicine department to exclude any possible technical 
error or imaging artefacts that might interfere with the end result. 
 
4.5.4 Imaging  Interpretation 
 
The semiquantitative visual SPECT interpretation was done using short axis, 
vertical long axis and horizontal axis views tomograms by two experienced Nuclear 
Medicine physicians. If there is disagreement, a discussion is held and a final 
conclusion or diagnosis pertaining to the image interpretation is obtained. The 17 
segment model is used for image interpretation with a five point score for each 
segment: 0 = Normal; 1 = Mildly reduced; 2 = Moderately reduced; 3 = Severely 
reduced; 4 = Absent tracer uptake.  Inducible ischaemia or reversible perfusion defect 
was defined as a perfusion defect on stress images that partially or completely 
resolved at rest images in two or more contiguous segments or slices. (Sarullo et al., 
2002, Ziessman et al., 2013).  
The  automated semiquantitative analysis using Cedar Sinai software was done 
to generate summed difference score (SDS). SDS was derived as a difference from 
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summed stress score (SSS) and summed rest score (SRS) which reflected the burden 
of ischaemia. The classifications of scoring consisted of mild = 2-4; moderate = 5-6, 
severe = ≥7 (Czaja et al., 2017). From SDS score, percentage of ischemic myocardium 
can be obtained given formula of SDS divided by 68 times 100. The 17 segments 
scoring with maximum score of 4 yielded the denominator value of 68.  
QGS parameters, which consisted of LVEF, EDV and ESV values were studied 
for completion of data on MPS findings. These were the normal values used as 
reference for this study; LVEF = 47-53%, EDV: male = 79 - 161ml; female = 60 – 
107ml, ESV: male = 36 – 74ml; female = 25 – 44ml(Lomsky et al., 2008). 
 
4.5.5 Patients Follow up 
Patients were followed up after 12 months of MPS were done. This was to 
evaluate whether patient had undergone revascularization namely Percutaneous 
Coronary Intervention (PCI) or Coronary Bypass Artery Surgery (CABG). Patients were 
contacted via phone to assess for any presence of hard events (which includes death, 
non-fatal myocardial infarction and severe heart failure) or no hard events (uneventful 
and non of the above).   
Cardiac death was confirmed by review of death certificate while non-fatal 
myocardial infarction was determined with appropriate ECG changes and/or elevated 
cardiac enzymes level.  Degree of heart failure severity was defined with New York 
Heart Association (NYHA) either NYHA III (Marked limitation of physical activity. Less 
than ordinary physical activity leads to symptoms) and IV (Unable to carry on any 
physical activity without discomfort. Symptoms of Chronic Heart Failure present at rest) 
fall into severe categories (Tonkin et al., 2005, Yancy et al., 2013). 
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 4.6 STUDY OUTCOME MEASURE AND FOLLOW UP 
 
A total of 103 patients who had met the inclusion and exclusion criteria were 
followed up, 12 months after baseline MPS. They were reached via phone and 
evaluation of presence of cardiac hard events at 12 months after MPS was recorded. 
Cardiac hard events include death, recurrent MI and severe heart failure. Types of 
intervention were also observed, whether the patients had undergone revascularisation 
or continued with medical therapy.  
This study consisted of primary and secondary outcome. Primary outcome 
consisted of types of management of patients carried out after MPS was done which 
was either revascularisation or continue with medical therapy. For objective 1, all 
independent risk factors and variables in MPS findings were analysed in relation to 
types of management.   
For objective 2, prevalence of cardiac hard events, 12 months after baseline 
was also described.  
Secondary outcome on the other hand consisted of presence of cardiac hard 
events or no cardiac hard events. Therefore, for objective 3, all independent risk 
factors, variables in MPS findings and types of management were analysed in relation 
to presence of cardiac hard events.  
 4.7 DATA ANALYSIS 
Statistical analyses were performed using IBM Statistical Package for Social 
Science software version 22 for Mac (SPSS, 2013). Descriptive statistics were 
expressed as frequency (percentage), mean ± standard deviation for normal data or 
median (IQR) for skewed data. Comparison between two groups was performed using 
Chi-square test, with Fischer Exact’s correction where appropriate. For unpaired data, 
the differences in distribution between two groups were analysed by independent-t test 
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or Mann-Whitney test according to normal or skewed distribution of the data. P value of 
0.05 and less was considered as significant. 
Univariate analysis using binary simple logistic regression was used to 
determine the relationship between independent variables and dependant variables. 
Reference variable is determined when the group has the lowest possible value for 
what the outcome may be. When the group is identified, the interpretation of 
significance is made easier. The result would produce crude odds ratio with 95% 
confidence interval and p value<0.05 is considered to be significant. Those variables 
with value of p<0.05 in univariate analysis were required for entry into multivariate 
analysis.  The analysis was to predict the probability that end observation that fall of 
one of two categorics of dichotomous dependant variable based on one or more 
independent variables that can be either continuous or categorical 
(statistics.laerd.com). 
4.8 ETHICS AND DISCLOSURE 
 
Research procedures followed were in accordance with the ethical standards of 
the Helsinki Declaration of 1964, revised in 2013 (World Medical Association, 2013) 
and Malaysian Guideline for Good Clinical Practice (National Committee for Clinical 
Research, 2011). This study had been approved by the Medical Research Ethics 
Committee (MREC) of the Malaysian Ministry of Health and registered with the 
National Medical Research Register (NMRR ID: NMRR-15-1991-35487) (APPENDIX 
H). Written informed consent was obtained from all patients. Confidentiality was strictly 
maintained, and data rendered anonymous except for the purpose of subject 
identification during statistical analysis. 
The author had no conflicts of interest to disclose, which may influence the 
impartiality of this study. 
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RESULTS 
 
5.1 DEMOGRAPHIC RESULTS 
 
A total of 103 patients who fulfilled the inclusion and exclusion criteria were 
selected. The mean age of patients who were referred for MPS was 55.1 years old. 
Male patients predominated the female with 79 (76.7%) patients. The ethnic group 
breakdown were 67 (65.0%) Malay, followed by 26 (25.2%) Chinese and 10 (9.7%) 
Indian. As for the risk factors, dyslipidaemia was the highest, which accounted for 81 
patients (78.6%) followed by HPT 67 patients (65.0%) and DM 60 patients (53.3%). 
These results were shown in Table 5.1. 
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Table 5.1: Characteristics of patients with history of STEMI referred for SPECT MPS 
(n=103) 
 
 
 
 
 
 
 
 
 
 
Characteristics Category Frequency (%) or 
Mean(SD) 
p value 
Age  Mean      55.1(9.0) 
 
0.31 
Gender Male 
Female 
79(76.7) 
24(23.3) 
 
0.22 
Race Malay 
Chinese 
Indian 
67(65.0) 
26(25.2) 
10(9.7) 
 
0.33 
Risk factors    
BMI  Mean      25.0(4.2) 
 
0.06 
Diabetes mellitus 
 
 60(58.3) 0.33 
Hypertension 
 
 67(65.0) 0.51 
Dyslipidaemia 
 
 81(78.6) 0.78 
Active smoking 
 
 46(44.7) 
 
0.09 
Family history 
 
 29(28.2) 0.66 
